NCT04890145已完成不适用
The RW-Precision-Coupler Clinical Investigation
MED-EL Elektromedizinische Geräte GesmbH2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2021年5月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Freiburger Monosyllable Test
研究概览
简要总结
The RW-Precision-Coupler Clinical Investigation is prospective, non-randomized, open label, single subjects repeated measures, longitudinal monocentric trial. The primary aim of this pre-market clinical investigation is to evaluate the clinical performance and safety of VSB together with the VSB RWP-Coupler in the treatment of hearing loss. As secondary aims are to evaluate the clinical performance of VSB together with RWP-Coupler by measuring Sound Field audiometry (SF), to evaluate the safety of VSB together with RWP-Coupler by measuring bone conduction (BC) thresholds and collecting and assessing adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Geographically and physically able to return to the investigational site for scheduled evaluations and follow-up appointments
- •Fluent in the German language
- •Persons of 18 years of age or older
- •Signed and dated informed consent before the start of any study-specific procedure
- •The physician must fully assess the potential risks and benefits for the patient prior to the decision to implant the RW-Precision-Coupler. The physician must exercise medical judgment and consider the patient's complete hospital record (also called medical history)
- •No previous active middle ear implant surgery performed in the implanted ear
- •The following indication for VORP503:
- •For a patient with sensorineural hearing loss, pure-tone air conduction threshold levels at or within the levels listed below:
- •For a patient with conductive or mixed hearing loss, pure tone bone-conduction threshold levels at or within the levels listed below:
- •A patient shall present with an ear anatomy that can facilitate positioning of the FMT in contact with a suitable vibratory structure of the ear.
- •A patient with sensorineural hearing loss shall be a current user of an acoustic hearing aid and have used this aid for at least 4 hours (average) per day for at least 3 months prior to evaluation, or shall not be able to wear or benefit from conventional hearing aids for medical reasons.
- •A patient shall be psychologically and emotionally stable with realistic expectations of the benefits and limitations of the Soundbridge
排除标准
- •Simultaneous participation in another clinical trial (on device or on drug) which would interfere with the results of the study
- •Pregnancy or lactation
- •Contraindication for RWP-Coupler Sizer:
- •if a patient is known to be intolerant of the materials used in the RWP-Coupler.
- •if a patient is known to be intolerant of the materials used in the RWP-Coupler Sizer.
- •in case of a fixed stapes footplate.
- •Contraindication for VORP503:
- •A patient is known to be intolerant of the materials used in the implant (medical grade silicone elastomer, medical grade epoxy and titanium).
- •A patient with retrocochlear, or central auditory disorders.
- •A patient with nonresponsive active ear infection and/or chronic fluid in or about the ear.
- •A patient whose hearing loss has demonstrated an improving and decreasing fluctuation over a two-year period of 15 dB in either direction.
- •A patient with any physical, psychological, or emotional disorder that would interfere with surgery or the ability to perform on test and rehabilitation procedures.
- •A patient with a skin or scalp condition that may preclude attachment of the audio processor with a magnet.
结局指标
主要结局
Freiburger Monosyllable Test
时间窗: 6 months post-operative
Investigate the improvement of unaided pre-activation Word Recognition Scores (WRS) to 6 months post-operation aided WRS with RW-Precision-Coupler
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Single Center Study to Evaluate the Safety of the NovaCross Microcatheter in Crossing Chronic Total OcclusionsChronic Total OcclusionNCT04862559Nitiloop Ltd.15
Unknown
2 期
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)Small Cell Lung CancerNCT02995187Chinese Academy of Medical Sciences25
已完成
1 期
Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.Healthy AdultsNCT03168022Tonix Pharmaceuticals, Inc.43
已完成
1 期
Study to Evaluate the Effect of Food Upon the Pharmacokinetics of AndroxalNormal VolunteersNCT02146391Repros Therapeutics Inc.12
已完成
不适用
Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA in CADCoronary Artery DiseaseNCT03284229Spectranetics Corporation28